NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression

Clinical Cancer Research

Volumn 9, Issue 17, 2003, Pages 6483-6488

  Omholt, Katarina ^a   Platz, Anton ^a   Kanter, Lena ^a   Ringborg, Ulrik ^a   Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GLYCINE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; SERINE; THREONINE; VALINE;

ADULT; AGED; ARTICLE; BRAF GENE; CODON; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE ACTIVATION; GENE INSERTION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICRODISSECTION; NRAS GENE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN BIOPSY; SKIN CARCINOGENESIS; TUMOR GROWTH;

ADULT; AGED; CODON; DISEASE PROGRESSION; DNA; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENES, RAS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; TREATMENT OUTCOME;

EID: 0348223934     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. van't Veer, L. J., Burgering, B. M. T., Versteeg, R., Boot, A. J. M., Ruiter, D. J., Osanto, S., Schrier, P. I., and Bos, J. L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol., 9: 3114-3116, 1989.
2. Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon-Cardo, C., McNutt, N. S., Bressler, J., and Andreeff, M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene, 4: 1363-1374, 1989.
3. Ball, N. J., Yohn, J. J., Morelli, J. G., Norris, D. A., Golitz, L. E., and Hoeffler, J. P. Ras mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol., 102: 285-290, 1994.
4. 1 checkpoint control are frequently mutated in human melanoma metastases. Br. J. Cancer, 74: 936-941, 1996.
5. van Elsas, A., Zerp, S. F., van der Flier, S., Krüse, K. M., Aarnoudse, C., Hayward, N. K., Ruiter, D. J., and Schrier, P. I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol., 149: 883-893, 1996.
6. Jiveskog, S., Ragnarsson-Olding, B., Platz, A., and Ringborg, U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol., 111: 757-761, 1998.
7. Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U., and Hansson, J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin. Cancer Res., 8: 3468-3474, 2002.
8. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
9. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., and Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet., 33: 19-20, 2003.
10. Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J. A., Albelda, S. M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P. A., Wooster, R., Stratton, M. R., and Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 62: 6997-7000, 2002.
11. Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z., and Aaronson, S. A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res., 63: 3883-3885, 2003.
12. Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A. N., Busam, K., and Polsky, D. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res., 63: 3955-3957, 2003.
13. Peyssonnaux, C., and Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell, 93: 53-62, 2001.
14. Barnier, J. V., Papin, C., Eychene, A., Lecoq, O., and Calothy, G. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J. Biol. Chem.. 270: 23381-23389, 1995.
15. Marais, R., Light, Y., Paterson, H. F., Mason, C. S., and Marshall, C. J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem., 272: 4378-4383, 1997.
16. Mason, C. S., Springer, C. J., Cooper, R. G., Superti-Furga, G., Marshall, C. J., and Marais, R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J., 18: 2137-2148, 1999.
17. Zhang, B. H., and Guan, K. L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J., 19: 5429-5439, 2000.
18. Hanks, S. K., and Hunter, T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J., 9: 576-596, 1995.
19. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (Lond.), 418: 934, 2002.
20. Singer, G., Oldt, R., III, Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., and Shih, I. M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst., 95: 484-486, 2003.
21. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., and Fagin, J. A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res., 63: 1454-1457, 2003.
22. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., Horner, J. W., II, Cordon-Cardo, C., Yancopoulos, G. D., and DePinho, R. A. Essential role for oncogenic Ras in tumour maintenance. Nature (Lond.), 400: 468-472, 1999.
23. Clark, W. H., Jr., Elder, D. E.. and Van Horn, M. The biologic forms of malignant melanoma. Hum. Pathol., 17: 443-450, 1986.
24. Clark, W. H., Jr., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., and Halpern, A. C. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst., 81: 1893-1904, 1989.
25. Demunter, A., Ahmadian, M. R., Libbrecht, L., Stas, M., Baens, M., Scheffzek, K., Degreef, H., De Wolf-Peeters, C., and van den Oord, J. J. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res., 61: 4916-4922, 2001.
26. Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., and van den Oord, J. J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol., 117: 1483-1489, 2001.
27. Nataraj, A. J., Olivos-Glander, I., Kusukawa, N., and Highsmith, W. E., Jr. Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis, 20: 1177-1185, 1999.